RxDoctor Payments Data

Troy Fate, MD

Family Medicine · Delaware, OHNPI 1174514269

Payments from drug & device makers

$7,976in general payments, 2019–2025

Across 394 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$933
  • Abbott$839
  • Novo Nordisk$696
  • AstraZeneca$515
  • Lilly USA, LLC$385
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$7,939100%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,976 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$89,042
Medicare patients
252
Services billed
973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$127,478
EliquisApixaban77$88,543
JardianceEmpagliflozin79$87,757
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$61,144
MounjaroTirzepatide57$59,951
TrulicityDulaglutide44$56,854
XareltoRivaroxaban16$17,343
JanuviaSitagliptin Phosphate14$16,227
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$8,530
Janumet XrSitagliptin Phos/Metformin Hcl13$8,213
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$6,827
SynthroidLevothyroxine Sodium61$4,258
Rosuvastatin Calcium200$4,250
Celecoxib90$4,102
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$696$127,47884 claims
Lilly USA, LLCMounjaro, Trulicity$385$116,805101 claims
PfizerEliquis$933$88,54377 claims
Boehringer IngelheimJardiance$20$87,75779 claims
GSKTrelegy Ellipta$253$61,14447 claims
MerckJanuvia, Janumet Xr$180$24,44027 claims
AbbVieSynthroid$1,311$4,25861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Delaware

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →